Trials / Completed
CompletedNCT01209208
Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis
Double-blind, Double-dummy, Randomised, Placebo-controlled, Multi-centre Phase III Study on the Efficacy and Tolerability of a 8-week Treatment With Budesonide vs. Mesalazine vs. Placebo in Patients With Lymphocytic Colitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Dr. Falk Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether budesonide or mesalazine is more active in the treatment of lymphocytic colitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Budesonide | 9 mg per day |
| DRUG | Mesalamine | 3 g per day |
| OTHER | Placebo | 0 g per day |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2010-09-27
- Last updated
- 2017-07-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01209208. Inclusion in this directory is not an endorsement.